Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) reported full‑year 2025 total revenue of $146.1M and U.S. XPOVIO net product revenue of $114.9M. The company reiterated 2026 guidance of $130M–$150M total revenue and $115M–$130M U.S. XPOVIO revenue.
Key clinical catalysts include Phase 3 SENTRY top‑line data expected in March 2026 and Phase 3 XPORT‑EC‑042 data expected in mid‑2026. Cash and financing items drove a $196.0M net loss for 2025 and a cash balance of $64.1M at year‑end.
Positive
- Total revenue $146.1M for full year 2025
- U.S. XPOVIO net revenue $114.9M in 2025
- Phase 3 SENTRY top‑line data expected March 2026
- Phase 3 XPORT‑EC‑042 top‑line data expected mid‑2026
- Loss from operations improved 24% year‑over‑year
Negative
- Net loss $196.0M for full year 2025
- Cash and investments $64.1M as of December 31, 2025
- Loss on extinguishment of debt $62.4M in 2025
- Interest expense $45.8M for full year 2025
Market Reaction
Following this news, KPTI has gained 18.32%, reflecting a significant positive market reaction. Our momentum scanner has triggered 24 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $8.72. This price movement has added approximately $25M to the company's valuation. Trading volume is above average at 1.6x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
KPTI is up 11.84% while peers show mixed moves (e.g., CAMP +2.86%, CUE -3.65%, MAIA -2.75%), pointing to a stock-specific reaction rather than a sector-wide biotech move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 03 | Q3 2025 earnings | Positive | +4.7% | Revenue growth, reaffirmed 2025 guidance and SENTRY enrollment completion. |
| Aug 11 | Q2 2025 earnings | Negative | -4.3% | Decent revenue but cash decline and need for financing alternatives. |
| May 12 | Q1 2025 earnings | Negative | -20.0% | Lower XPOVIO revenue, sizable net loss and limited cash runway. |
| Nov 05 | Q3 2024 earnings | Neutral | -9.4% | Steady revenue, narrowed guidance and continued net losses with cash buffer. |
| Aug 06 | Q2 2024 earnings | Positive | -3.6% | Strong quarter with net income, raised guidance and improved cash. |
Earnings headlines have historically led to volatile trading with an average move of -6.51%, skewed toward negative reactions despite mixed fundamentals.
Over the past year, Karyopharm’s earnings updates have focused on steady XPOVIO revenue, reaffirmed guidance, and advancing the Phase 3 SENTRY myelofibrosis program toward a March 2026 readout. Liquidity commentary has repeatedly emphasized runway only into the second quarter of 2026 and the need for financings or strategic alternatives. Prior quarters showed both net losses and one quarter of net income, with guidance generally maintained or narrowed. Today’s full-year 2025 results and 2026 guidance build directly on that trajectory of operational discipline and late‑stage clinical execution.
Historical Comparison
In the last five earnings-related releases, KPTI’s average move was -6.51%, usually skewing negative. Today’s +11.84% reaction to full-year 2025 results and 2026 guidance stands out as a sharp upside outlier versus that history.
Earnings releases have tracked stable XPOVIO revenue, tightened expense guidance, and steady progress of the Phase 3 SENTRY program toward the planned March 2026 top-line readout, while repeatedly flagging a liquidity runway into the second quarter of 2026.
Regulatory & Risk Context
An effective S-3 resale registration covers up to 2,805,688 shares of common stock, including 1,487,917 outstanding shares and 1,317,771 shares underlying warrants. The company is not selling securities in this offering and receives cash only if the registered warrants are exercised.
Market Pulse Summary
The stock is surging +18.3% following this news. A strong positive reaction aligns with investors focusing on revenue stability and visible catalysts. Full-year 2025 revenue of $146.1M and XPOVIO sales of $114.9M matched prior preliminary figures, while 2026 guidance of $130M–$150M keeps expectations anchored. Historically, earnings moves averaged -6.51%, so a +11.84% gain marked a sharp upside deviation that could be sensitive to changing views on cash of $64.1M and the SENTRY Phase 3 readout timing.
Key Terms
phase 3 medical
treatment-emergent adverse events medical
AI-generated analysis. Not financial advice.
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –
– Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 –
– Total Revenue was
– Company Provides Full-Year 2026 Total Revenue Guidance of
– Conference Call Scheduled for Today at 8:00 a.m. ET –
"As we enter 2026, Karyopharm is approaching a defining period marked by important upcoming clinical milestones and a continued focus on disciplined execution, positioning the Company at a potential inflection point," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "While selinexor has established a durable commercial foundation in multiple myeloma within a highly competitive treatment landscape, our late-stage programs in myelofibrosis and endometrial cancer represent an opportunity to fundamentally expand the impact and scale of our franchise."
"Top-line data from our Phase 3 SENTRY trial in myelofibrosis are expected in March, and our organization is energized and well positioned to support the next phase of this program. If SENTRY is successful, we have the potential to meaningfully improve outcomes for patients and introduce the first-ever combination therapy in myelofibrosis, a setting with significant unmet need. In endometrial cancer, we remain on track to report top-line data in mid-2026 from our Phase 3 trial evaluating selinexor in a defined, biomarker-driven patient population with limited effective treatment options. With the upcoming myelofibrosis readout as a key near-term catalyst and endometrial cancer representing a subsequent opportunity for further expansion, 2026 positions Karyopharm at a potential inflection point as we work to translate our science into durable patient impact and long-term value creation," added Mr. Paulson.
Fourth Quarter 2025 Highlights
XPOVIO Commercial Performance
U.S. net product revenue was$114.9 million $112.8 million U.S. net product revenue for the fourth quarter of 2025 was$32.1 million $29.3 million - Demand for XPOVIO was consistent in 2025 versus 2024 in the highly competitive multiple myeloma marketplace, with the community setting continuing to drive approximately
60% of overall net product revenue. - Global patient access for selinexor expanded in 2025, with favorable reimbursement decisions in
Spain andChina , and additional regulatory approvals in multiple countries with selinexor now approved in more than 50 countries.
Research and Development (R&D) Highlights
Myelofibrosis
- Completed enrollment in early September 2025 of the Phase 3 SENTRY trial (XPORT-MF-034; NCT04562389) which is evaluating 60 mg once-weekly selinexor in combination with ruxolitinib compared to ruxolitinib plus placebo in 353 JAKi-naïve patients with myelofibrosis. The preliminary baseline characteristics for patients enrolled in SENTRY as presented at the American Society of Hematology 2025 Annual Meeting (n=320) are representative of the intended patient population. In addition, preliminary blinded aggregate safety data from the first 61 patients with a median follow-up of greater than 12 months may suggest improvements in both hematologic and non-hematologic treatment-emergent adverse events as compared to the Phase 1 data evaluating selinexor 60 mg weekly in combination with standard of care ruxolitinib in JAKi-naïve myelofibrosis patients, as well as historical ruxolitinib monotherapy data. The Company cautions that preliminary baseline characteristics and preliminary blinded aggregate safety data from the Phase 3 SENTRY trial may not ultimately be reflective of the actual trial results.
Endometrial Cancer
- Enrollment continues in the Phase 3 XPORT-EC-042 trial (NCT05611931) evaluating selinexor as a maintenance-only therapy following systemic therapy versus placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer.
Multiple Myeloma
- Enrollment in the Phase 3 XPORT-MM-031 trial (EMN29; NCT05028348) was completed in the fourth quarter of 2024 (n=117). The trial is being conducted in collaboration with the European Myeloma Network and is evaluating the all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 in their immediate prior line of therapy.
Anticipated Catalysts and Operational Objectives
Myelofibrosis
- Top-line data from the Phase 3 SENTRY trial is expected in March 2026.
- Top-line data from all patients in the 60 mg cohort of the Phase 2 SENTRY-2 trial (NCT05980806) with at least 24 weeks of follow-up is expected in the second half of 2026. The Company continues to enroll patients into the Phase 2 SENTRY-2 trial.
Endometrial Cancer
- Top-line data from the event-driven, Phase 3 XPORT-EC-042 trial is expected in mid-2026. The Company continues to enroll patients into the XPORT-EC-042 trial of selinexor as a maintenance monotherapy for patients with TP53 wild-type advanced or recurrent endometrial cancer.
Multiple Myeloma
- Maintain the Company's commercial foundation in the increasingly competitive multiple myeloma marketplace and drive increased XPOVIO revenues.
- Continue to support global launches by our partners following regulatory and reimbursement approvals for selinexor in ex-
U.S. territories. - Top-line data from the event-driven, Phase 3 XPORT-MM-031 (EMN29) trial is expected in the second half of 2026.
2026 Financial Outlook
Based on its current operating plans, Karyopharm expects the following for full year 2026:
- Total revenue to be in the range of
$130 million $150 million U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners. U.S. XPOVIO net product revenue to be in the range of$115 million $130 million - R&D and selling, general and administrative (SG&A) expenses to be in the range of
$230 million $245 million - The Company expects its existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will enable it to fund its current operating plans into the second quarter of 2026.
Full Year and Fourth Quarter 2025 Financial Results
Total revenue: Total revenue for the fourth quarter of 2025 was
Net product revenue: Net product revenue was
License and other revenue: License and other revenue was
Cost of sales: Cost of sales was
R&D expenses: R&D expenses were
SG&A expenses: SG&A expenses were
Loss from operations: Loss from operations was
Interest income: Interest income was
Interest expense: Interest expense was
(Loss) gain on extinguishment of debt: (Loss) gain on extinguishment of debt was a loss of
Other (expense) income, net: Other (expense) income, net was
Net loss: Net loss was
Cash position: Cash, cash equivalents, restricted cash and investments as of December 31, 2025 totaled
Conference Call Information
Karyopharm will host a conference call today, February 12, 2026, at 8:00 a.m. Eastern Time, to discuss the fourth quarter 2025 financial results, the financial outlook for 2026 and to provide other business updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website. An archived webcast will be available on the Company's website approximately two hours after the event.
About the Phase 3 SENTRY Trial
SENTRY (XPORT-MF-034; NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L. Patients are randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction ≥
About Myelofibrosis
Myelofibrosis is a rare blood cancer that affects approximately 20,000 patients in
1. Clarivate/DRG (2023) |
2. Palandri, F., Palumbo, G.A., Elli, E.M. et al. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J. 11, 4 (2021). |
3. Pardanani, A., & Tefferi, A. (2011). Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis. Haematologica, 96(1), 8–10. |
About the Phase 3 XPORT-EC-042 Trial
EC-042 (XPORT-EC-042; NCT05611931) is a global, Phase 3, randomized, double-blind clinical trial evaluating selinexor as a maintenance therapy following systemic therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer. The EC-042 trial is expected to enroll approximately 276 patients who will be randomized 1:1 to receive either a 60 mg, once-weekly, administration of oral selinexor or placebo until disease progression. The trial includes two patient populations, for which, the primary endpoint of progression free survival will be tested sequentially: 1) a modified intent to treat population (mITT) that will include patients with either, a) TP53 wild-type tumors with proficient mismatch repair status (pMMR); or, b) TP53 wild-type tumors with deficient mismatch repair status (dMMR), who are medically ineligible to receive checkpoint inhibitors; and, 2) the trial's original intent to treat (ITT) population, which includes all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. The key secondary endpoint of overall survival will be evaluated in the ITT population. The mITT population is expected to include approximately 220 patients. In connection with the EC-042 trial, Karyopharm entered into a global collaboration with Foundation Medicine, Inc. to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test to identify and enroll patients whose tumors are TP53 wild-type.
About Endometrial Cancer
Endometrial cancer (EC) is the most common gynecologic malignancy in the
1. American Cancer Society. Cancer Facts & Figures 2026. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf. Accessed February 8, 2026 |
2. IARC GLOBOCAN 2022, Global Estimates |
3. Lu KH, et al. N Engl J Med. 2020;383:2053-2064 |
4. NCI. Cancer stat facts: uterine cancer. https://seer.cancer.gov/statfacts/html/corp.html. Accessed October 7, 2025 |
5. American Cancer Society, Endometrial Cancer Risk Factors, 2025 |
6. Leslie KK, et al. Gynecol Oncol. 2021;161(1):113-121. |
7. Vergote I, et al. J Clin Oncol. 2023;41(35):5400-5410. |
8. Mirza MR, et al. Presentation at: ESMO Congress; October 20-24, 2023 |
9. Mirza MR, et al. N Engl J Med. 2023; 388:2145-2158. |
10. Eskander RN, et al. N Eng J Med. 2023;388:2159-2170. |
11. Makker V, et al. Gynecol Oncol. 2024 Jun:185: 202-211 |
About XPOVIO® (selinexor)
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the
For more information about Karyopharm's products or clinical trials, please contact the Medical Information department at: Tel: +1 (888) 209-9326; Email: medicalinformation@karyopharm.com
XPOVIO® (selinexor) is a prescription medicine approved:
- In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd).
- In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).
- For the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care.
- Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony‐stimulating factors.
- Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care.
- Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care.
- Serious Infection: Monitor for infection and treat promptly.
- Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes.
- Embryo‐Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception.
- Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract.
Adverse Reactions
- The most common adverse reactions (≥
20% ) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3‐4 laboratory abnormalities (≥10% ) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia. In theBOSTON trial, fatal adverse reactions occurred in6% of patients within 30 days of last treatment. Serious adverse reactions occurred in52% of patients. Treatment discontinuation rate due to adverse reactions was19% . - The most common adverse reactions (≥
20% ) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in9% of patients. Serious adverse reactions occurred in58% of patients. Treatment discontinuation rate due to adverse reactions was27% . - The most common adverse reactions (incidence ≥
20% ) in patients with DLBCL, excluding laboratory abnormalities, are fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, and pyrexia. Grade 3‐4 laboratory abnormalities (≥15% ) are thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia. In the SADAL trial, fatal adverse reactions occurred in3.7% of patients within 30 days, and5% of patients within 60 days of last treatment; the most frequent fatal adverse reactions was infection (4.5% of patients). Serious adverse reactions occurred in46% of patients; the most frequent serious adverse reaction was infection (21% of patients). Discontinuation due to adverse reactions occurred in17% of patients.
Use In Specific Populations
Lactation: Advise not to breastfeed.
For additional product information, including full prescribing information, please visit www.XPOVIO.com.
To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1‐888‐209‐9326 or FDA at 1‐800‐FDA‐1088 or www.fda.gov/medwatch.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2026 total revenue, 2026 U.S. net product revenue and 2026 R&D and SG&A expenses; expected cash runway and liquidity; Karyopharm's beliefs about the market opportunity and annual peak revenue opportunities for selinexor; expectations with respect to commercialization efforts; expectations regarding the timing of reporting top-line data from ongoing clinical trials; the ability of selinexor to treat patients with multiple myeloma, endometrial cancer, myelofibrosis, diffuse large B-cell lymphoma and other diseases; and expectations with respect to the clinical development plans and potential regulatory submissions of selinexor. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
KARYOPHARM THERAPEUTICS INC. | ||||||||||||||||
Three Months Ended | Years Ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenues: | ||||||||||||||||
Product revenue, net | $ | 32,090 | $ | 29,252 | $ | 114,857 | $ | 112,806 | ||||||||
License and other revenue | 1,989 | 1,290 | 31,210 | 32,431 | ||||||||||||
Total revenue | 34,079 | 30,542 | 146,067 | 145,237 | ||||||||||||
Operating expenses: | ||||||||||||||||
Cost of sales | 1,484 | 1,331 | 5,949 | 6,007 | ||||||||||||
Research and development | 27,667 | 33,302 | 125,617 | 143,232 | ||||||||||||
Selling, general and administrative | 22,772 | 27,190 | 105,208 | 115,441 | ||||||||||||
Total operating expenses | 51,923 | 61,823 | 236,774 | 264,680 | ||||||||||||
Loss from operations | (17,844) | (31,281) | (90,707) | (119,443) | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest income | 607 | 1,482 | 2,773 | 7,400 | ||||||||||||
Interest expense | (12,619) | (11,204) | (45,849) | (37,422) | ||||||||||||
(Loss) gain on extinguishment of debt | (62,365) | — | (62,365) | 44,702 | ||||||||||||
Other (expense) income, net | (10,044) | 10,114 | 152 | 28,398 | ||||||||||||
Total other (expense) income, net | (84,421) | 392 | (105,289) | 43,078 | ||||||||||||
Loss before income taxes | (102,265) | (30,889) | (195,996) | (76,365) | ||||||||||||
Income tax provision | 67 | 109 | (43) | (57) | ||||||||||||
Net loss | $ | (102,198) | $ | (30,780) | $ | (196,039) | $ | (76,422) | ||||||||
Basic net loss per share | $ | (5.71) | $ | (3.67) | $ | (17.93) | $ | (9.41) | ||||||||
Diluted net loss per share | $ | (5.71) | $ | (3.67) | $ | (17.93) | $ | (14.00) | ||||||||
Weighted-average number of common shares | 17,904 | 8,392 | 10,935 | 8,125 | ||||||||||||
Weighted-average number of common shares | 17,904 | 8,392 | 10,935 | 8,455 | ||||||||||||
All share amounts and per share amounts in this press release have been adjusted to reflect a 1-for-15 reverse split of our | ||||||||||||||||
KARYOPHARM THERAPEUTICS INC. | |||||||
December 31, | December 31, | ||||||
Assets | |||||||
Cash, cash equivalents and investments | $ | 63,744 | $ | 108,712 | |||
Restricted cash | 351 | 338 | |||||
Accounts receivable | 26,178 | 30,766 | |||||
Other assets | 18,143 | 24,602 | |||||
Total assets | $ | 108,416 | $ | 164,418 | |||
Liabilities and stockholders' deficit | |||||||
Convertible senior notes due 2025 | $ | — | $ | 24,426 | |||
Convertible senior notes due 2028 | 21,117 | — | |||||
Convertible senior notes due 2029 | 89,973 | 68,345 | |||||
Senior secured term loan | 115,805 | 94,603 | |||||
Deferred royalty obligation | 72,338 | 73,499 | |||||
Other liabilities | 102,109 | 89,562 | |||||
Total liabilities | 401,342 | 350,435 | |||||
Total stockholders' deficit | (292,926) | (186,017) | |||||
Total liabilities and stockholders' deficit; 18,311 and 8,413 shares issued and | $ | 108,416 | $ | 164,418 | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-company-progress-302685810.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
When will KPTI report Phase 3 SENTRY top‑line data for myelofibrosis?
What revenue guidance did Karyopharm (KPTI) provide for full year 2026?
How did KPTI perform commercially with XPOVIO in 2025?
What is Karyopharm's cash runway and liquidity outlook as of February 2026?
What were the major drivers of KPTI's 2025 net loss of $196.0M?
When are top‑line data expected for Karyopharm's endometrial cancer Phase 3 trial (XPORT‑EC‑042)?
